Investors

Corporate Profile

LAVA Therapeutics N.V. is a developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The company’s innovative approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct, selective tumor cell killing. The company’s lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.

Latest Events

January 18, 2022 at 5:00 PM PST

Dr. Parren will present preclinical data on LAVA’s lead solid tumor Gammabody™ LAVA-1207 as well as new non-human primate data supporting the safety and tolerability profile of LAVA’s lead solid tumor Gammabody™ programs.

Presenter: Paul W.H.I. Parren, Ph.D., Executive Vice President, Head of Research and Development
Presentation Title: Bispecific Gamma-Delta T Cell Engagers Targeting PSMA for the Treatment of Prostate Cancer
Location: San Diego and virtual – Sapphire Session Room

Data Provided by Refinitiv. Minimum 15 minutes delayed.